Cancer discovery | 2021
Infigratinib Approved for Cholangiocarcinoma.
Abstract
The FDA has approved the FGFR2 inhibitor infigratinib for patients with locally advanced or metastatic cholangiocarcinoma who have already been treated for the disease. In a phase II study, the overall response rate for the drug was 23%, and the progression-free survival was 7.3 months. About 77% of patients developed hyperphosphatemia, the most common side effect of the drug.